» Download Public Reports
About 300 reports
- Company report
- December 2012
- 222 pages
... Corporation, as well as its subsidiary, adma plasma biologics, inc., A delaware corporation, taken as a whole, and also refer to the operations of adma plasma biologics, inc. Prior to the merger on february 13 ...
December 2012
... To _______ commission file no. 000-50746 cord blood america, inc. (Exact name of registrant as specified in its charter) florida 90-0613888 (state or other jurisdiction of incorporation or organization) (i.R.S. Employer ...
December 2012
... To advancing the science and commercialization of peripheral nerve repair solutions, announced today that the journal of hand surgery published new clinical results for use of avance nerve graft for repair ...
December 2012
... Ushered in a new era, one that has seen the company become the world S third-largest producer of plasma-derived medicines as it builds a new future on the basis of the group S expansion following ...
February 2013
... Of these adverse reactions from blood transfusions is 1 in 394 transfusions, a number believed to be even higher because of underreporting, according to the most recent data from the national blood collection ...
April 2013
... Q4 12 q1 12 q2 12 q3 12 q4 475,000 500,000 525,000 550,000 575,000 600,000 american red cross blood centers of america source: blood centers of america and arcinternal data accounting for >60% of us ...
March 2013
... Not requiring cold storage (e.G. Modified, plasma, platelets, & red blood cells and oxygen carrying solutions) % rapid low technology screening tests for infectious diseases % pathogen reduced blood ...
March 2013
... Process. These processes are activated at the blood banks. Almost 90% of the blood supply in the united states, as well as 80% of transfusions, is co-ordinated through these blood banks, and other publicly ...
April 2013
... Of transfusions while ensuring each patient is looked at as an individual definitions of patient blood management percentage of hospital blood bankdirectors/managers conservative transfusion approach 20% evaluating ...
February 2013
... Injury in dcd grafts Modify allocation rules to increase access to retransplantation after failed dcd liver transplants Refine understanding of risk factors of dcd liver transplants http ...
» Purchase Premium Reports
(From $ 125 - $ 3 400)
93 reports
- $ 3 400
- Industry report
- March 2013
- by TriMark Publications
Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement. As such, astounding new advancements in ...
March 2013
$ 2 732
Report Details Biobanks - what are their technological and commercial prospects? See what the future holds for biobanking in human medicine. Visiongain's updated report gives you its revenue predictions ...
March 2013
$ 2 000
Kidney Transplantation - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Kidney Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. ...
February 2013
$ 2 000
Bone Marrow Transplantation - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Bone Marrow Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic ...
April 2013
$ 1 020
IBISWORLD INDUSTRY RISK RATINGS REPORT This is the replacement for IBISWorld's November Blood & Organ Banks in the US Industry Risk Ratings Report. Industry Risk Ratings Synopsis This Industry Risk Ratings ...
March 2013
$ 800
Recent scientific studies are leading to the discovery of new proteins in the blood plasma and their uses to treat hitherto unresolved medical conditions. The industry for blood plasma products has shown ...
May 2013
$ 750
Summary TEI Biosciences, Inc. (TEI) is a biomedical company. The company develops and commercializes novel biological products for soft tissue repair, reconstruction and reinforcement applications. Its ...
